Our Partners

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes especially pharmaceutical products and medical imaging agents. The company’s portfolio includes contrast media, nuclear imaging agents, branded medicines, generic drugs and active pharmaceutical ingredients. For more information about Mallinckrodt, please visit: www.mallinckrodt.com

therakos photopheresis partner mealis

THERAKOS (UK) Ltd. has had a long-standing commitment to supporting global excellence in clinical education and training related to autologous immune cell therapy delivered through extracorporeal photopheresis (ECP). THERAKOS now became part of Mallinckrodt Pharmaceuticals, which is a leading specialty biopharmaceutical company, focusing on two missions: Managing Complexity and Improving Lives.

For more information about THERAKOS (UK) Ltd., please visit: www.therakos.co.uk

KOEK Biotechnology Ltd., founded in 2012, with the mission of developing and commercializing novel microfluidic technology to: 

– Deliver improvements in assisted reproductive technology (ART) and andrology
– Enable advances in life science research and applied markets
– Provide faster and more cost effective biotechnology-based products
KOEK Biotechnology is the global supplier of microfluidic – based technology – namely Microfluidic Sperm Sorting Technology developed in Demirci Bio-Acustic MEMS in medicine labs (BAMM labs) at Brigham & Women’s hospital and addressing the needs in fertility and andrology clinicsFor more information about KOEK Biotechnology, please visit: http://www.koekbiotech.com/

SITZMARKS® Radiopaque Markers are the simple, reliable, and affordable method of diagnosis of many gastrointestinal (GI) conditions, including chronic constipation, colonic inertia, hypomotility, outlet delay, and bowel obstruction. 
This unique colonic transit diagnostic test helps professionals select the best therapeutic option for adult patients with severe constipation who have otherwise negative GI evaluations.
For more information about Sitzmarks please visit: http://www.sitzmarks.com

At the core of Mirion Technologies is a dedicated team with unmatched expertise and experience. The Company is well positioned to extend its global franchise based upon the renaissance of the global nuclear power industry; strong global demand for homeland security and defense solutions; and increased utilization of radiological medical applications. Mirion will continue to maintain a technology leadership position through innovative products and solutions.
To learn more about Mirion, visit: www.mirion.com

Calmed began operating in 1949, with disposable plastic products for healthcare and other uses. Today the main focus is on accessories for radiography of the colon, such as colon bags, rectal nozzles and air pumps. The main product is the Calmed CT1400, a CO2 insufflator for CT colonography with an associated unique tube set. 
For more information about Calmed please visit: www.calmed.se

ITM Isotope Technologies München AG was founded in 2004 and is a privately held group of radiopharmaceutical companies, dedicated to development and proprietary production of novel radiopharmaceuticals and radiomedical devices. 
For more information please visit: 
www.itg-garching.de

Global Medical Solutions Ltd. was formed in 2003 to be a leading-edge provider of nuclear medicine and diagnostic imaging products and services. Global Medical Solutions’ core businesses consist of the overseas units of the former Syncor International. Global Medical Solutions’ mission is to continue the long history of providing quality products and services to the worldwide nuclear medicine community. 
For more information about GMS please visit: http://globalmedicalsolutions.com

 

Pharmalucence, a Sun Pharma Company, is a New England based, manufacturer of human injectable pharmaceuticals.
Their team of greater than 120 professionals performs manufacturing services of non-cytotoxic human injectables in either liquid or lyophilized form. Their new 70,000 sq. ft. facility is the region’s first to utilize fully automated and isolated aseptic technology in support of a wide array of needs, from small clinical fills up to full commercial scale production for markets worldwide. This new facility, combined with their twenty plus years of experience and expertise, will provide their customers with compliance beyond currently mandated requirements
To learn more about Pharmalucence, visit: www.pharmalucence.com